Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesalazine + ursodeoxycholic acid
- Development stage
- Preclinical
- Lead developer
- Tillotts Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of mesalazine and ursodeoxycholic acid (UDCA). This combination has shown better therapeutic effects than mesalazine alone in patients with ulcerative colitis, possibly due to changes in the IL-23-IL-17 axis and beneficial alterations in intestinal microflora distribution. The combination therapy results in lower levels of inflammatory markers and improved clinical outcomes as measured by Mayo scores and Inflammatory Bowel Disease Questionnaire scores.
02
Targets
Beyond the preview
Go deeper on mesalazine + ursodeoxycholic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesalazine + ursodeoxycholic acid.